Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated stage IV lung adenocarcinoma confirmed at MSKCC~* Age 18 years or older~* Karnofsky Performance Status ≥ 70~* Patients with locally treated, stable, and/or asymptomatic brain metastases are eligible.~* Adequate bone marrow, liver and renal function, as specified below:~* Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L~* Hemoglobin ≥ 8 g/dL~* Platelets ≥ 100 x 109/L~* Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)~* AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present~* Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal.~* Negative PPD test~* For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment~* Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter~* Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors~* Archival tissue (10 Unstained Slides - 5 micron sections) from a core biopsy performed and received within 30 days before signing consent or ability to have a fresh core biopsy performed~* Biopsy cannot be from any cytology or bone specimen~* Biopsy site must be amenable to re-biopsy at the end of the study~* Ability to provide written, informed consent~Exclusion Criteria:~* Hypersensitivity to platinum agents~* Ongoing use of investigational agents or use of investigational agents within the last four weeks~* Prior use of agents for TNF-alpha blockade~* History of rheumatoid arthritis, inflammatory bowel disease, or psoriatic arthritis~* Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)~* Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush~* Active tuberculosis or untreated, latent tuberculosis~  o If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.~* Acute or chronic Hepatitis B or C infection~* Known HIV infection requiring antiretroviral medications and those with AIDS~* Active herpes zoster infection~* Non-healed infected skin ulcers~* History of myocardial infarction or unstable angina within the past 12 months~* Ongoing use of other immunosuppressive medications, including oral steroids and excluding topical steroids~* Women who are breastfeeding Prior history of other malignancy with the exclusion of localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- certolizumab, cisplatin and pemetrexed (Type: EXPERIMENTAL): Patients will receive certolizumab with 6 cycles of cisplatin \& pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, \& subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg \& 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete